Accessibility helpSkip to navigationSkip to contentSkip to footer

Cookies on FT Sites

We use cookies for a number of reasons, such as keeping FT Sites reliable and secure, personalising content and ads, providing social media features and to analyse how our Sites are used.

Accept & continue
Manage cookies
  • Sign In
  • Subscribe
Open side navigation menuOpen search bar
Financial Times
SubscribeSign InmyFT
  • Home
  • World
    Sections
    • World Home
    • Global Economy
    • UK
    • US
    • China
    • Africa
    • Asia Pacific
    • Emerging Markets
    • Europe
    • War in Ukraine
    • Americas
    • Middle East & North Africa
    • Australia & NZ
    Most Read
    • Boris Johnson to resign as prime minister as UK government crumbles
    • Who will replace Boris Johnson as UK prime minister?
    • Boris Johnson sacks Michael Gove as even allies tell him ‘game’s up’
    • Boris Johnson bows to pressure and quits after days of turmoil
    • Russia prepares to mobilise economy for longer war in Ukraine
  • US
    Sections
    • US Home
    • US Economy
    • US Companies
    • US Politics & Policy
    Most Read
    • In the ultimate coup for the right, it’s Justice Thomas’s Supreme Court now
    • Federal Reserve officials warn entrenched inflation poses ‘significant risk’
    • Cathie Wood’s flagship Ark fund draws in $1.5bn even as tech stocks tumble
    • America’s unending horizon of mass shootings
    • Leadership: Six Studies in World Strategy by Henry Kissinger
  • Companies
    Sections
    • Companies Home
    • Energy
    • Financials
    • Health
    • Industrials
    • Media
    • Professional Services
    • Retail & Consumer
    • Tech Sector
    • Telecoms
    • Transport
    Most Read
    • Russian oligarch-backed LetterOne sues PE firm that manages its billions
    • How China’s BYD played catch-up with Tesla
    • French state plans to take full control of EDF
    • Rajeev Misra to launch new $6bn fund backed by Abu Dhabi groups
    • Shell to revise up value of oil and gas assets
  • Tech
  • Markets
    Sections
    • Markets Home
    • Alphaville
    • Markets Data
    • Capital Markets
    • Commodities
    • Currencies
    • Equities
    • Fund Management
    • Trading
    • Moral Money
    • ETF Hub
    • Cryptocurrencies
    Most Read
    • Boris Johnson latest updates: Dominic Raab will not stand in leadership contest
    • Live news updates from July 6: More than 40 members of UK government quit, Boris Johnson sacks Michael Gove
    • Recession speculation comes for commodities
    • Pound climbs as UK prime minister Boris Johnson resigns
    • Pound traders look past UK political turmoil
  • Climate
  • Opinion
    Sections
    • Opinion Home
    • Columnists
    • The FT View
    • The Big Read
    • Lex
    • Obituaries
    • Letters
    Most Read
    • The departure of Boris Johnson is long overdue
    • Boris Johnson goes, but what comes next?
    • Boris Johnson’s era is at an end as Tories rush for the exit
    • Lying politicians are a product of society’s devaluing of truth
    • Johnson’s successor will have to repair Britain’s status abroad
  • Work & Careers
    Sections
    • Work & Careers Home
    • Business School Rankings
    • Business Education
    • Entrepreneurship
    • Recruitment
    • Business Books
    • Business Travel
    Most Read
    • Michael Lewis: ‘The thing that really works for Trump is: the system’s rigged’
    • Meet the founders with the boomerang factor
    • British Rail: A New History — a timely reminder of how to run a railway
    • Pop-up leaders and flexible staff are ready for a new crisis
    • Help truly wanted, even if you’ve been in jail
  • Life & Arts
    Sections
    • Life & Arts Home
    • Arts
    • Books
    • Food & Drink
    • FT Magazine
    • House & Home
    • Style
    • Travel
    • FT Globetrotter
    Most Read
    • In the ultimate coup for the right, it’s Justice Thomas’s Supreme Court now
    • Chess: Nepo wins Candidates again as Carlsen asks for new world title format
    • Leadership: Six Studies in World Strategy by Henry Kissinger
    • HMRC victory in Alan Parry tax case raises uncertainty for freelance workers
    • The fantastic spending habits of Mr Roald Dahl
  • HTSI
MenuSearch
  • Home
  • World
  • US
  • Companies
  • Tech
  • Markets
  • Climate
  • Opinion
  • Work & Careers
  • Life & Arts
  • HTSI
Financial Times
SubscribeSign In

Your guide to a disrupted world

Start a 4-week trial

Johnson & Johnson Co Inc

Add to myFT Digest

Add this topic to your myFT Digest for news straight to your inbox

  • Tuesday, 21 June, 2022
    Behind the Money podcast28 min listen
    Inside Johnson & Johnson’s bankruptcy two-step

    This legal manoeuvre is setting a new precedent for corporations to evade accountability in America

  • Sunday, 6 March, 2022
    J&J targets Chinese biotech deals as western pharma groups look east

    US drugmaker seeks more tie-ups after existing collaboration yields new cancer treatment

  • Tuesday, 1 March, 2022
    LexBankruptcy
    US bankruptcy/J&J: new turn for Texas two-step Premium content

    Ruling opens a fresh chapter for resolving US tort cases

  • Monday, 28 February, 2022
    Health
    US lawmakers plan bill to outlaw ‘Texas two-step’ bankruptcy ploy

    Fight moves to Congress after judge allows J&J to use scheme to help it settle billions in legal claims

  • Friday, 25 February, 2022
    Johnson & Johnson can proceed with controversial bankruptcy strategy, judge rules

    Decision allows group to use the manoeuvre to manage tens of thousands of claims that its baby talc caused cancer

  • Monday, 14 February, 2022
    Legal services
    Architects of ‘Texas two-step’ lambast J&J for its use of the manoeuvre

    Lawyer who drafted statute says companies should not deploy it to ‘skirt’ their obligations

  • Thursday, 6 January, 2022
    Covid-19 vaccines
    Covid vaccine makers face investor pressure over global access

    Asset managers call for pharma executive pay to be linked to equitable distribution of jabs

  • Thursday, 30 December, 2021
    Covid-19 vaccines
    Johnson & Johnson booster slashes risk of Omicron hospitalisation, study shows

    Two doses cut likelihood by up to 85%, according to real-world South African research

  • Sunday, 12 December, 2021
    South Africa
    South Africa’s leader Cyril Ramaphosa tests positive for Covid

    Country tackles one of the first waves of infections caused by Omicron variant

  • Wednesday, 1 December, 2021
    ExplainerCovid-19 vaccines
    Will Covid vaccines have to be updated for Omicron?

    Drugmakers are stress-testing existing jabs while preparing new formulas

  • Monday, 29 November, 2021
    FT live news
    News updates from November 29: WHO warns of ‘very high’ risk from Omicron, Dorsey resigns as Twitter CEO, German inflation hits 6%
  • Friday, 19 November, 2021
    News in-depth
    Johnson & Johnson touts ‘golden moment’ to pursue pharma-led future

    Plan to spin off consumer division has failed to thrill investors

  • Monday, 15 November, 2021
    The FT ViewThe editorial board
    Conglomerates’ cycle of break-ups turns again

    Advisers benefit from multinationals’ current wave of spin-offs

  • Friday, 12 November, 2021
    Lex
    Johnson & Johnson: the break-up band-aid comes off Premium content

    A successful split of the consumer and pharma divisions would, on paper, unlock value

  • Friday, 12 November, 2021
    Johnson & Johnson to spin off consumer business

    World’s largest healthcare group follows trend to slim down with plans to focus on pharmaceuticals

  • Thursday, 28 October, 2021
    J&J’s ‘Texas-two-step’ sparks outcry over US bankruptcy regime

    World’s largest healthcare company uses unusual legal manoeuvre to contain talc-based baby powder liabilities

  • Thursday, 21 October, 2021
    The FT ViewThe editorial board
    J&J’s Texas two-step waltzes over its liabilities

    Abusive deployment of Chapter 11 protection can erode consumer confidence

  • Wednesday, 20 October, 2021
    Covid-19 vaccines
    FDA approves Moderna and J&J Covid booster shots

    People at high risk of catching coronavirus can now receive any of three vaccines authorised by US health agency

  • Tuesday, 19 October, 2021
    Corporate earnings and results
    J&J spent $1.4bn on legal move to shield it from talc cancer claims

    Healthcare group created a subsidiary to manage allegations then placed it into bankruptcy

  • Friday, 15 October, 2021
    J&J puts newly created subsidiary into bankruptcy over talc claims

    Lawyer for plaintiffs claims drugmaker is trying to limit payouts to cancer sufferers

  • Thursday, 14 October, 2021
    Covid-19 vaccines
    FDA advisers back Moderna’s Covid booster for at-risk groups

    Panel recommends third jabs for vulnerable people in step towards expanding US rollout of extra doses

  • Tuesday, 7 September, 2021
    Covid-19 vaccines
    Pfizer chief says enough Covid doses to meet WHO’s vaccine goal

    Albert Bourla believes it is ‘feasible’ to inoculate at least 10% of people in every country

  • Wednesday, 25 August, 2021
    Covid-19 vaccines
    J&J says Covid booster shot produced strong antibody response

    Data come amid debate over whether additional jabs are needed to increase protection

  • Friday, 20 August, 2021
    Lex
    J&J: new CEO offers continuity Premium content

    Company veteran Joaquin Duato, Gorsky’s longtime protégé, takes up the reins

  • Thursday, 19 August, 2021
    J&J veteran Joaquin Duato to take over as chief executive

    Incoming chief executive has overseen health products and drugmaker’s response to Covid-19

Previous page You are on page 1 Next page

Useful links

Support

View Site TipsHelp CentreContact UsAbout UsAccessibilitymyFT TourCareers

Legal & Privacy

Terms & ConditionsPrivacy PolicyCookiesCopyrightSlavery Statement & Policies

Services

Share News Tips SecurelyIndividual SubscriptionsGroup SubscriptionsRepublishingExecutive Job SearchAdvertise with the FTFollow the FT on TwitterFT ChannelsSecondary Schools

Tools

PortfolioToday's Newspaper (ePaper)Alerts HubBusiness School RankingsEnterprise ToolsNews feedNewslettersCurrency Converter

Community & Events

FT CommunityFT LiveFT ForumsFT Board DirectorBoard Director Programme

More from the FT Group

Markets data delayed by at least 15 minutes. © THE FINANCIAL TIMES LTD 2022. FT and ‘Financial Times’ are trademarks of The Financial Times Ltd.
The Financial Times and its journalism are subject to a self-regulation regime under the FT Editorial Code of Practice.
Financial Times

International Edition

Subscribe for full access
  • Switch to UK Edition
  • Top sections
  • Home
  • World
    • Global Economy
    • UK
    • US
    • China
    • Africa
    • Asia Pacific
    • Emerging Markets
    • Europe
    • War in Ukraine
    • Americas
    • Middle East & North Africa
    • Australia & NZ
  • US
    • US Economy
    • US Companies
    • US Politics & Policy
  • Companies
    • Energy
    • Financials
    • Health
    • Industrials
    • Media
    • Professional Services
    • Retail & Consumer
    • Tech Sector
    • Telecoms
    • Transport
  • Tech
  • Markets
    • Alphaville
    • Markets Data
    • Capital Markets
    • Commodities
    • Currencies
    • Equities
    • Fund Management
    • Trading
    • Moral Money
    • ETF Hub
    • Cryptocurrencies
  • Climate
  • Opinion
    • Columnists
    • The FT View
    • The Big Read
    • Lex
    • Obituaries
    • Letters
  • Work & Careers
    • Business School Rankings
    • Business Education
    • Entrepreneurship
    • Recruitment
    • Business Books
    • Business Travel
  • Life & Arts
    • Arts
    • Books
    • Food & Drink
    • FT Magazine
    • House & Home
    • Style
    • Travel
    • FT Globetrotter
  • Personal Finance
    • Property & Mortgages
    • Investments
    • Pensions
    • Tax
    • Banking & Savings
    • Advice & Comment
    • Next Act
  • HTSI
  • Special Reports
  • FT recommends
  • Lex
  • Alphaville
  • Lunch with the FT
  • FT Globetrotter
  • #techAsia
  • Moral Money
  • FTfm
  • Newsletters
  • Video
  • Podcasts
  • News feed
  • FT Community
    • FT Live
    • FT Forums
    • Board Director Programme
  • myFT
  • Portfolio
  • Today's Newspaper (ePaper)
  • Crossword
  • Our Apps
  • Help Centre
  • Subscribe
  • Sign In